These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11596851)

  • 1. Neuroleptic effects on autonomic activity in schizophrenia: between-group and within-subject paradigms and comparisons with controls.
    Zahn TP; Pickar D; van Kammen DP
    Schizophr Bull; 2001; 27(3):503-15. PubMed ID: 11596851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine.
    Zahn TP; Pickar D
    Biol Psychiatry; 1993 Jul 1-15; 34(1-2):3-12. PubMed ID: 8104043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.
    Zahn TP; Pickar D; Haier RJ
    Schizophr Res; 1994 Sep; 13(2):133-44. PubMed ID: 7986770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autonomic activity in relation to symptom ratings and reaction time in unmedicated patients with schizophrenia.
    Zahn TP; Pickar D
    Schizophr Res; 2005 Nov; 79(2-3):257-70. PubMed ID: 16006104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
    Chouinard G; Annable L; Ross-Chouinard A; Kropsky ML
    J Clin Psychiatry; 1979 Mar; 40(3):147-52. PubMed ID: 33969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.
    Aruna AS; Murungi JH
    Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
    Doran AR; Labarca R; Wolkowitz OM; Roy A; Douillet P; Pickar D
    Arch Gen Psychiatry; 1990 Jun; 47(6):558-63. PubMed ID: 2350208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
    Jain RC; Ananth JV; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral fluphenazine versus placebo for schizophrenia.
    Matar HE; Almerie MQ
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006352. PubMed ID: 17253589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroleptic effects on electrodermal responsivity to soft tones and loud noise in schizophrenia.
    Green MF; Nuechterlein KH
    Psychiatry Res; 1988 Apr; 24(1):79-86. PubMed ID: 2899332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of symptomatology and medication to electrodermal activity in schizophrenia.
    Green MF; Nuechterlein KH; Satz P
    Psychophysiology; 1989 Mar; 26(2):148-57. PubMed ID: 2567035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 20. Fluphenazine decanoate causing atrioventricular block.
    Rao AV
    Indian Heart J; 1996; 48(6):713-4. PubMed ID: 9062027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.